AI-Ready, GMP-Compliant Digital Infrastructure for NGS-Based CQA Assessment Across Biotherapeutic Development and Manufacturing

August 25, 2026

Biopharmaceutical manufacturing increasingly relies on advanced analytics to ensure the quality, safety, and consistency of cell lines used in the production of novel biotherapeutics. While next-generation sequencing (NGS) provides insights into Critical Quality Attributes, such as genetic identity, integrity, and safety, broader adoption across R&D and manufacturing continues to be limited by fragmented workflows, siloed data, and poor interoperability.
Genedata Selector^® provides a fully digitalized framework that streamlines NGS assay development and execution in GMP-compliant environments. The platform integrates multi-omics and bioprocess data, creating a FAIR-compliant foundation for AI-driven analytics and data-informed decision-making. It seamlessly connects sequencing instruments with ELN, LIMS, and bioprocess systems to automate high-throughput workflows, standardize assay design, and enable audit-ready reporting with embedded quality checkpoints. By consolidating metadata, raw and processed sequencing data, and metabolomics and proteomics datasets within a unified ecosystem, Genedata Selector establishes an AI/ML-ready data layer that supports predictive modeling and advanced analytics. This digital infrastructure bridges the gap between cell-based product development and manufacturing, enabling faster, data-driven decisions, improving scalability, and reducing risk from discovery through commercial production.